In the third of the three significant decisions issued in the In re Zantac MDL, No. 2924, on New Year’s Eve, preemption prevailed again – this time barring claims asserted against drug retailers and pharmacists, both branded and generic. In re Zantac (Ranitidine) Products Liability Litigation, ___ F. Supp.3d ___, 2020 WL 7864585 (S.D.
Zantac Chronicles II – The Prevalence of Preemption
Another of the recent significant decisions from the In re Zantac MDL, No. 2924, addressed preemption – mostly but not entirely involving defendants who manufactured generic versions of the drug. In re Zantac (Ranitidine) Products Liability Litigation, ___ F. Supp.3d ___, 2020 WL 7864213 (S.D. Fla. Dec. 31, 2020). For those who have not
Update on COVID-19 Litigation & Federal Jurisdiction
Those of you following the fortunes of COVID-19-related litigation should check out these two recently decided cases: Garcia v. Welltower OpCo Group LLC, 2021 WL 492581 (C.D. Cal. Feb. 10, 2021), and Fields v. Brown, 2021 WL 510620 (E.D. Tex. Feb. 11, 2021).
Garcia, the older of the two (by one day),
Zantac Chronicles – No Innovative, or Innovator, Liability
Several significant decisions have recently emerged from the In re Zantac MDL, No. 2924. We gave you a “bare bones” rundown of the first four of them right away. But now we’d like to discuss them in more detail.
We start with In re Zantac (Ranitidine) Products Liability Litigation, ___ F. Supp.3d
Guest Post – A Trip In The Wayback Machine Reveals What FDA Has In Store for Artificial Intelligence/Machine Learning in Medical Devices
We’re interested in artificial intelligence, particularly as it affects medical devices, but we don’t know all that much about it, and it’s yet to make much of an impact in our product liability sandbox. Fortunately, we know some folks who do stay informed on this topic, and that’s what today’s guest post is about. In
Guest Post − Building A Better Bellwether
Today’s guest post is by the Reed Smith team of Shana E. Russo, Jennifer A. Eppensteiner, and Kathy I. Oviedo. It is about multi-district litigation (“MDL”) practice, and specifically, compares and contrasts various ways of selecting plaintiffs for possible bellwether trials. It also useful in providing links to orders entered in a
Preemption Again Defeats Breast Implant Claims
We praised Brooks v. Mentor Worldwide, LLC, 2019 WL 4628264 (D. Kan. Sept. 23, 2019), when it was first decided, as “checking all the boxes.” Last week the Tenth Circuit affirmed, and believe us, it rechecked all those boxes.
In Brooks v. Mentor Worldwide LLC, ___ F.3d ___, 2021 WL 245246
Reflections on Turning 65
Bexis just turned 65 (on 1/25/2021) – the classic retirement age. That’s an occasion to look back and evaluate what’s gone on over the course of an entire legal career. So how have we done, as defense lawyers, over the course of our entire careers, at our primary job – which is to prevail for
Appellate Commentary on MDL Master Complaints
We’ve complained before about MDL “master” or “consolidated” complaints being used to deprive defendants of the ability to pursue their rights to seek dismissal on TwIqbal and other pleading-related grounds. In individual actions, defendants have the right to put the plaintiffs’ pleadings to the test required by Rules 8 and 12. That has not necessarily
Shameless Plug — CLE Webinar on the best and worst drug/medical device decisions of 2020
As 2020 ended, our loyal readers joined us in reviewing our worst decisions of the past year – true superspreaders of litigation against our clients – and our best decisions of the past year, which we termed “tort pandemic countermeasures.”
As we do each year, we’re pleased to announce that four of your bloggers